查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球移植診斷市場：按技術、產品、應用、類型、最終用戶和地區劃分的未來預測（至 2028 年）
市場調查報告書
商品編碼
1258207

全球移植診斷市場：按技術、產品、應用、類型、最終用戶和地區劃分的未來預測（至 2028 年）

Transplant Diagnostics Market by Technology, Product, Application, Type, End User & Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 254 Pages | 訂單完成後即時交付

價格
簡介目錄

到 2028 年，全球移植診斷市場規模預計將從 2022 年的 44 億美元增長到 68 億美元，預測期內的複合年增長率為 7.4%。

對於許多依賴透析的終末期慢性腎病患者來說，移植是最重要的治療選擇之一。 此外，即使涉及心臟、肝臟和骨髓的病例也可以通過移植治療。 此外，在過去十年中，公司在開發更好的 HLA 分型技術、抗體監測、工具和軟件方面取得了長足進步。 它越來越多地用於各種身體器官移植過程中的診斷目的。 這些因素有助於擴大移植診斷市場。

“到2022年，腎移植將佔據最大市場份額”

按移植類型劃分，腎移植將在 2022 年佔據最大的市場份額。 由於預期壽命的延長以及肥胖、糖尿病和高血壓的增加，慢性腎髒病流行，需要血液透析的患者數量不斷增加。 這些因素正在增加腎移植的市場份額。

“到2022年，基於分子的檢測技術將佔據最大份額”

基於分子的檢測技術市場進一步細分為基於 PCR 的分子檢測和基於序列的分子檢測。 基於 PCR 的分子檢測比基於測序的檢測（Sanger 測序、NGS 測序等）佔有更大的份額。

“北美市場將在預測期內實現最高增長”

到 2022 年，北美將佔據最大的市場份額 (45.5%)。 私人和公共資金的增加以及公眾對器官捐獻意識的提高促成了北美的高份額。

另一方面，亞太地區有望在未來幾年內實現顯著增長。 預計亞太移植診斷市場在預測期內將以 8.3% 的複合年增長率增長，這主要是由於亞洲國家醫院數量的增加和有利的政府舉措。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 簡介
  • 市場動態
    • 司機
    • 約束因素
    • 機會
    • 任務
  • 經濟衰退對移植診斷市場的影響

第 6 章移植診斷市場：按技術分類

  • 簡介
    • 分子檢測技術
    • 非分子檢測技術

第 7 章移植診斷市場：按產品/服務分類

  • 簡介
    • 試劑和耗材
    • 設備
    • 軟件服務

第 8 章移植診斷市場：按應用

  • 簡介
    • 診斷用途
    • 研究用途

第 9 章移植診斷市場：最終用戶

  • 簡介
  • 獨立參考研究所
  • 醫院和移植中心
  • 研究和教育機構

第 10 章。移植診斷市場：按移植類型分類

  • 簡介
    • 實體器官移植
    • 幹細胞移植
    • 軟組織移植
    • 骨髓移植

第 11 章移植診斷市場：按地區

  • 簡介
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第12章競爭格局

  • 簡介
  • 主要公司採用的策略
  • 市場份額分析
  • 競爭場景
  • 競爭領導力映射

第13章公司簡介

  • 主要公司
    • BIO-RAD LABORATORIES
    • F. HOFFMANN-LA ROCHE LTD.
    • QIAGEN NV
    • BECTON, DICKINSON AND COMPANY
    • BIOFORTUNA
    • BIOMERIEUX SA
    • CAREDX
    • GENDX
    • HOLOGIC, INC.
    • ILLUMINA, INC.
    • IMMUCOR, INC.
    • LUMINEX CORPORATION
    • MERCK KGAA
    • OMIXON
    • THERMO FISHER SCIENTIFIC
  • 其他企業
    • ALPHABIOTECH LIMITED
    • BAG DIAGNOSTICS GMBH
    • HANSA BIOPHARMA AB
    • HISTOGENETICS LLC
    • PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • TBG DIAGNOSTICS LIMITED
    • TAKARA BIO INC.
    • INNO-TRAIN DIAGNOSTIK GMBH

第14章 附錄

簡介目錄
Product Code: MD 4870

The transplant diagnostic market is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period. For many patients with chronic dialysis-dependent end-stage renal disease, transplantation is one of their top treatment choices. Additionally, cases involving the heart, liver, and bone marrow can be treated with transplantation. Additionally, over the past ten years, companies have made significant strides in developing better HLA typing technologies, antibody monitoring, tools, and software. This is gradually being used for diagnostic purposes when transplanting various body organs. These are the factors contributing to increasing transplant diagnostic market.

"The Kidney transplants to hold the largest share of the market in 2022"

According to transplant type, the kidney transplant holds the largest market share in 2022. Due to longer lifespans and rising rates of obesity, diabetes, and hypertension, chronic kidney disease is becoming more prevalent and there are more patients needing hemodialysis.These factors are causing an increase in the market share for kidney transplants.

"The Molecular based assay technology is holding the largest share of the market in 2022"

Based on technology, the molecular-based assay technology market is classified into PCR-based Molecular assays and Sequencing based molecular assays. The PCR-based molecular assays hold a larger share than sequencing-based assays like sanger sequencing and NGS sequencing.

"The market in North America region is expected to witness the highest growth during the forecast period."

North America accounted for the largest market share-45.5%-in 2022. The increasing private -public funding and increasing public awareness for organ donation is contributing to the high number of the share of North America.

While APAC is expected to witness significant growth in the coming years. The transplant diagnostic market in the APAC region is expected to register a CAGR of 8.3% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
  • By Designation: C-level-27%, Director-level-18and Others-55%
  • By Region: North America-45%, Europe-15%, Asia Pacific-20%, Latin America-15%, and the Middle East & Africa-5%

The prominent player in transplant diagnostic market are bioMerieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US)

Research Coverage

This report studies the transplant diagnostic market based on product&service, technology,application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN: TRANSPLANT DIAGNOSTICS MARKET
    • 2.1.1 SECONDARY DATA
    • FIGURE 2 KEY DATA FROM SECONDARY SOURCES
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
    • 2.3.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.4 RISK ASSESSMENT
    • TABLE 1 LIMITATIONS AND ASSOCIATED RISKS

3 EXECUTIVE SUMMARY

    • FIGURE 8 REAGENTS & CONSUMABLES TO CONTINUE TO DOMINATE TRANSPLANT DIAGNOSTICS MARKET UNTIL 2028
    • FIGURE 9 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR SEGMENT DOMINATED TRANSPLANT DIAGNOSTICS MARKET IN 2022
    • FIGURE 10 KIDNEY TRANSPLANTATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • FIGURE 11 INFECTIOUS DISEASE TESTING SEGMENT TO DOMINATE TRANSPLANT DIAGNOSTIC APPLICATIONS MARKET BY 2028
    • FIGURE 12 INDEPENDENT REFERENCE LABORATORIES TO DOMINATE MARKET DURING FORECAST PERIOD
    • FIGURE 13 REGIONAL SNAPSHOT OF TRANSPLANT DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 RISING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET
  • 4.2 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2028 (USD MILLION)
    • FIGURE 15 PCR-BASED MOLECULAR ASSAYS TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.3 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SHARE, BY END USER AND COUNTRY (2022)
    • FIGURE 16 INDEPENDENT REFERENCE LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.4 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022 VS. 2028 (USD MILLION)
    • FIGURE 17 HEART TRANSPLANTATION SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY
    • FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE IN TRANSPLANT DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing number of transplant procedures
      • 5.2.1.2 Technological advancements in transplant diagnostic procedures
      • 5.2.1.3 Increasing public-private funding for target research activities
    • TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR DEVELOPMENT OF TRANSPLANT DIAGNOSTIC PRODUCTS, 2018-2022
      • 5.2.1.4 Rising prevalence of infectious diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High procedural cost of NGS- and PCR-based diagnostic assays
    • TABLE 3 EUROPE: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS (2021)
      • 5.2.2.2 Limited reimbursement for target procedures
    • TABLE 4 US: MEDICAL REIMBURSEMENTS FOR TRANSPLANTATION PROCEDURES (2021)
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation
      • 5.2.3.2 Growing public awareness about organ donation and transplantation
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Significant gap between number of organ donors and organs required annually
      • 5.2.4.2 Procedural and technical limitations associated with donor-recipient screening
  • 5.3 IMPACT OF RECESSION ON TRANSPLANT DIAGNOSTICS MARKET

6 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 5 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • 6.1.1 MOLECULAR ASSAY TECHNOLOGIES
    • TABLE 6 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 7 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 8 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 9 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020-2028 (USD MILLION)
    • TABLE 10 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020-2028 (USD MILLION)
      • 6.1.1.1 PCR-BASED MOLECULAR ASSAYS
    • TABLE 11 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 12 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 13 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 14 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2020-2028 (USD MILLION)
    • TABLE 15 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.1.1 Sequence-specific oligonucleotide-PCR
          • 6.1.1.1.1.1 Most widely adopted technique in PCR-based molecular assays market
    • TABLE 16 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.1.2 Sequence-specific primer-PCR
          • 6.1.1.1.2.1 Growing public-private investments for research activities to support market growth
    • TABLE 17 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.1.3 Real-time PCR
          • 6.1.1.1.3.1 Requires smaller sample volume compared to conventional PCR technologies
    • TABLE 18 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.1.4 Other PCR-based molecular assays
    • TABLE 19 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)
      • 6.1.1.2 SEQUENCING-BASED MOLECULAR ASSAYS
    • TABLE 20 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 21 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 22 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 23 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2020-2028 (USD MILLION)
    • TABLE 24 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.2.1 Sanger sequencing
          • 6.1.1.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market
    • TABLE 25 TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.2.2 Next-generation sequencing
          • 6.1.1.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS
    • TABLE 26 TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020-2028 (USD MILLION)
        • 6.1.1.2.3 Other sequencing-based molecular assays
    • TABLE 27 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)
    • 6.1.2 NON-MOLECULAR ASSAY TECHNOLOGIES
      • 6.1.2.1 Replacement of non-molecular assay techniques with DNA-based techniques to hamper growth
    • TABLE 28 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 29 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 30 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020-2028 (USD MILLION)
    • TABLE 31 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020-2028 (USD MILLION)

7 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 32 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • 7.1.1 REAGENTS & CONSUMABLES
      • 7.1.1.1 Largest and fastest-growing segment of transplant diagnostics market
    • TABLE 33 TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2020-2028 (USD MILLION)
    • 7.1.2 INSTRUMENTS
      • 7.1.2.1 Increasing public-private investments to drive market
    • TABLE 34 TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2020-2028 (USD MILLION)
    • 7.1.3 SOFTWARE & SERVICES
      • 7.1.3.1 Growing automation & digitalization of diagnostic laboratory procedures to support market growth
    • TABLE 35 TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2020-2028 (USD MILLION)

8 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 36 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • 8.1.1 DIAGNOSTIC APPLICATIONS
    • TABLE 37 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 38 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)
      • 8.1.1.1 Pre-transplantation diagnostics
    • TABLE 39 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 40 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION)
        • 8.1.1.1.1 Infectious disease testing
          • 8.1.1.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market
    • TABLE 41 INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2020-2028 (USD MILLION)
        • 8.1.1.1.2 Histocompatibility testing
          • 8.1.1.1.2.1 Technological advancements and growing R&D activities to propel market
    • TABLE 42 HISTOCOMPATIBILITY TESTING MARKET, BY REGION, 2020-2028 (USD MILLION)
        • 8.1.1.1.3 Blood profiling
          • 8.1.1.1.3.1 Growing availability of molecular assay products to support market growth
    • TABLE 43 BLOOD PROFILING MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 8.1.1.2 Post-transplantation diagnostics
        • 8.1.1.2.1 Greater risk of disorders and infections post-transplantation makes diagnostics necessary step
    • TABLE 44 POST-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • 8.1.2 RESEARCH APPLICATIONS
      • 8.1.2.1 Growing funding for research to drive market
    • TABLE 45 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)

9 TRANSPLANT DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 46 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.1.1 INDEPENDENT REFERENCE LABORATORIES
      • 9.1.1.1 Rising consolidation of diagnostic laboratories to drive market
    • TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2020-2028 (USD MILLION)
    • 9.1.2 HOSPITALS & TRANSPLANT CENTERS
      • 9.1.2.1 Growing purchasing power of hospitals & transplant centers to support market growth
    • TABLE 48 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2020-2028 (USD MILLION)
    • 9.1.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
      • 9.1.3.1 Increasing industry-academia collaborations in genomics-based transplant diagnostic research to drive market
    • TABLE 49 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2020-2028 (USD MILLION)

10 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE

  • 10.1 INTRODUCTION
    • TABLE 50 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • 10.1.1 SOLID ORGAN TRANSPLANTATION
    • TABLE 51 SOLID ORGAN TRANSPLANTATION MARKET, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 52 SOLID ORGAN TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.1 Kidney transplantation
        • 10.1.1.1.1 Rising prevalence of kidney diseases to drive market
    • FIGURE 20 NUMBER OF KIDNEY TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
    • TABLE 53 KIDNEY TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.2 Liver transplantation
        • 10.1.1.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market
    • FIGURE 21 NUMBER OF LIVER TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
    • TABLE 54 LIVER TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.3 Lung transplantation
        • 10.1.1.3.1 Rising prevalence of chronic lung diseases to drive market
    • FIGURE 22 NUMBER OF LUNG TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
    • TABLE 55 LUNG TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.4 Heart transplantation
        • 10.1.1.4.1 Increasing prevalence of chronic cardiac diseases to propel market
    • FIGURE 23 NUMBER OF HEART TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
    • TABLE 56 HEART TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.5 Pancreas transplantation
        • 10.1.1.5.1 Procedural complexity and risk of surgical complications to restrain growth
    • FIGURE 24 NUMBER OF PANCREAS TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
    • TABLE 57 PANCREAS TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
      • 10.1.1.6 Other organ transplantation
    • TABLE 58 OTHER ORGAN TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
    • 10.1.2 STEM CELL TRANSPLANTATION
      • 10.1.2.1 Rising procedural volume and growing research activities to drive market
    • TABLE 59 STEM CELL TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
    • 10.1.3 SOFT TISSUE TRANSPLANTATION
      • 10.1.3.1 Technological advancements and rising prevalence of target diseases to drive market
    • TABLE 60 SOFT TISSUE TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)
    • 10.1.4 BONE MARROW TRANSPLANTATION
      • 10.1.4.1 Dearth of well-trained surgeons to perform bone marrow transplantation to hinder growth
    • TABLE 61 BONE MARROW TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)

11 TRANSPLANT DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 62 TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • 11.1.1 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 63 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 64 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 68 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 69 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)
      • 11.1.1.1 US
        • 11.1.1.1.1 Technological advancements in transplant diagnostics to drive market
    • FIGURE 26 US: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021
    • TABLE 71 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 72 US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 73 US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.1.2 Canada
        • 11.1.1.2.1 Growing availability of transplant diagnostic products to support market growth
    • FIGURE 27 CANADA: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021
    • TABLE 74 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 75 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 76 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • 11.1.2 EUROPE
    • TABLE 77 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 78 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 79 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 80 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 81 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 82 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 83 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • TABLE 84 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)
      • 11.1.2.1 GERMANY
        • 11.1.2.1.1 Largest market for transplant diagnostics in Europe
    • TABLE 85 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 86 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 87 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.2.2 UK
        • 11.1.2.2.1 Rising number of transplantation procedures to drive market
    • TABLE 88 UK: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
    • TABLE 89 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 90 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 91 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.2.3 France
        • 11.1.2.3.1 Increased adoption of molecular diagnostic techniques for donor-recipient compatibility testing to propel market
    • TABLE 92 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 93 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 94 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.2.4 Spain
        • 11.1.2.4.1 Rising number of solid organ transplantation procedures to drive market
    • TABLE 95 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 96 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 97 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.2.5 Italy
        • 11.1.2.5.1 Sluggish growth in healthcare sector to restrain market growth
    • TABLE 98 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 99 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 100 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.2.6 Rest of Europe
    • TABLE 101 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 102 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 103 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • 11.1.3 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 104 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 107 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)
      • 11.1.3.1 China
        • 11.1.3.1.1 Improvements in healthcare infrastructure to support market growth
    • TABLE 112 CHINA: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
    • TABLE 113 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 114 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 115 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.3.2 India
        • 11.1.3.2.1 Increasing number of transplantation procedures to drive market
    • TABLE 116 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 117 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 118 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.3.3 Japan
        • 11.1.3.3.1 Rising prevalence of chronic diseases to support market growth
    • FIGURE 29 JAPAN: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021
    • TABLE 119 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 120 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 121 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.3.4 Australia
        • 11.1.3.4.1 Rising number of solid organ transplantation procedures to drive market
    • TABLE 122 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 123 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 124 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.3.5 South Korea
        • 11.1.3.5.1 Government initiatives to introduce medical coverage for transplantation to drive market
    • TABLE 125 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 126 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 127 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.3.6 Rest of Asia Pacific
    • TABLE 128 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 129 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 130 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • 11.1.4 LATIN AMERICA
    • TABLE 131 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 132 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 133 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 134 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 135 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 136 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 137 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)
      • 11.1.4.1 Brazil
        • 11.1.4.1.1 Rising investments by leading transplant diagnostic manufacturers to favor market growth
    • TABLE 139 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 140 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 141 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.4.2 Mexico
        • 11.1.4.2.1 Rising medical tourism to support market growth
    • TABLE 142 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 143 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 144 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
      • 11.1.4.3 Rest of Latin America
    • TABLE 145 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 146 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 147 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • 11.1.5 MIDDLE EAST & AFRICA
      • 11.1.5.1 Developing healthcare infrastructure to favor market growth
    • TABLE 148 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)
    • TABLE 149 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 150 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 151 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)
    • TABLE 152 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 153 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)
    • TABLE 154 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
  • 12.3 MARKET SHARE ANALYSIS
    • FIGURE 31 TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
  • 12.4 COMPETITIVE SCENARIO
    • 12.4.1 PRODUCT LAUNCHES AND APPROVALS
    • 12.4.2 DEALS
  • 12.5 COMPETITIVE LEADERSHIP MAPPING
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 32 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 13.1.1 BIO-RAD LABORATORIES
    • TABLE 155 BIO-RAD LABORATORIES: COMPANY OVERVIEW (2021)
    • FIGURE 33 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 156 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW (2021)
    • FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.3 QIAGEN NV
    • TABLE 157 QIAGEN NV: COMPANY OVERVIEW (2021)
    • FIGURE 35 QIAGEN NV: COMPANY SNAPSHOT (2021)
    • 13.1.4 BECTON, DICKINSON AND COMPANY
    • TABLE 158 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW (2021)
    • FIGURE 36 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
    • 13.1.5 BIOFORTUNA
    • 13.1.6 BIOMERIEUX SA
    • TABLE 159 BIOMERIEUX SA: COMPANY OVERVIEW (2021)
    • FIGURE 37 BIOMERIEUX SA: COMPANY SNAPSHOT (2021)
    • 13.1.7 CAREDX
    • TABLE 160 CAREDX: COMPANY OVERVIEW (2021)
    • FIGURE 38 CAREDX: COMPANY SNAPSHOT (2021)
    • 13.1.8 GENDX
    • TABLE 161 GENDX: COMPANY OVERVIEW (2021)
    • 13.1.9 HOLOGIC, INC.
    • TABLE 162 HOLOGIC, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 39 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.10 ILLUMINA, INC.
    • TABLE 163 ILLUMINA, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.11 IMMUCOR, INC.
    • TABLE 164 IMMUCOR, INC.: COMPANY OVERVIEW (2021)
    • FIGURE 41 IMMUCOR, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.12 LUMINEX CORPORATION
    • TABLE 165 LUMINEX CORPORATION: COMPANY OVERVIEW (2021)
    • FIGURE 42 LUMINEX CORPORATION: COMPANY SNAPSHOT (2021)
    • 13.1.13 MERCK KGAA
    • TABLE 166 MERCK KGAA: COMPANY OVERVIEW (2021)
    • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021)
    • 13.1.14 OMIXON
    • TABLE 167 OMIXON: COMPANY OVERVIEW (2021)
    • 13.1.15 THERMO FISHER SCIENTIFIC
    • TABLE 168 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021)
    • FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
  • 13.2 OTHER PLAYERS
    • 13.2.1 ALPHABIOTECH LIMITED
    • 13.2.2 BAG DIAGNOSTICS GMBH
    • 13.2.3 HANSA BIOPHARMA AB
    • 13.2.4 HISTOGENETICS LLC
    • 13.2.5 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • 13.2.6 TBG DIAGNOSTICS LIMITED
    • 13.2.7 TAKARA BIO INC.
    • 13.2.8 INNO-TRAIN DIAGNOSTIK GMBH
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS